<DOC>
	<DOCNO>NCT02532647</DOCNO>
	<brief_summary>A prospective , double-blind , randomize , placebo active control , multi-center , parallel group study compare remimazolam placebo , additional open-label arm midazolam , ASA Grade III IV patient undergo colonoscopy diagnostic therapeutic reason .</brief_summary>
	<brief_title>Efficacy Safety Remimazolam ASA III IV Patients Undergoing Colonoscopy</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>male female patient , age â‰¥ 18 year , schedule undergo colonoscopy ASA grade III/IV patient patient know sensitivity benzodiazepine , flumazenil , opioids , naloxone , medical condition agent contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>